Free Daily Podcast Summary
BioSpace: Daily Summaries Delivered
by BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Yesterday21 min
Beyond the needle: The future of intratumoral therapy
In this episode of Denatured, you’ll hear from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anti-cancer immunity from a local injection, and redefine a foundational platform in immuno-oncology.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsLewis Bender, President & CEO, Intensity TherapeuticsPaul-Peter Tak, President, CEO and Board Director, Candel TherapeuticsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
- 2 days ago23 min
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare disease treatments; HHS greenlights the compounding of six unapproved peptides; and uniQure’s embattled gene therapy for Huntington’s disease has finally been accepted for review.
- 1 weeks ago21 min
Stability, speed and strategy: Inside Australia’s early‑stage edge
In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJerome Barley, Commercial Director, Avion MedicalRyan Klein, Vice President, Business Development, US and APAC, ResolianDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
- 1 weeks ago23 min
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to the presentation and antibody-drug conjugate sac-TMT making a splash in endometrial cancer; Bristol Myers Squibb revealed the death of a patient with multiple sclerosis in an early-stage trial of zola-cel; and pharma is on track to easily surpass last year’s deal count.
- 2 weeks ago18 min
Why investors are taking another look at kidney disease
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsBruce Culleton, CEO, ProKidneyDemetri Maxim, CEO, NephrogenDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
- 2 weeks ago17 min
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck and Summit Therapeutics.
- 2 weeks ago16 min
Bonus: Q3 2026 Job Market Update
BioSpace Vice President Chantal Dresner and Angela Gabriel, content manager, life sciences careers, cover what happened in the biopharma job market during the third quarter. They discuss encouraging signs for those looking for their next opportunity, such as improved job postings live on the BioSpace website and a dramatic drop in layoffs. Other topics include signs of industry health, news about job opportunities and advice for the Q4 job hunt.
- 3 weeks ago10 min
The decisions behind scientific progress
In this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we discuss how biopharma has long invested in more data and visibility, yet many programs still face delays and scale-up surprises. The real challenge isn’t information overload—it’s building confidence in the decisions that steer scientific progress from development through commercialization.This episode is presented in partnership with Cytiva. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestNicolas Pivet, VP & GM, Manufacturing & Digital Solutions, CytivaDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations
Get BioSpace summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
The Long Run with Luke Timmerman
In-depth conversations with biotech leaders navigating the challenges and opportunities of advancing science for human health.
Bloomberg Intelligence
Analysis of Wall Street investments and company research from Bloomberg Intelligence experts.
Bloomberg Intelligence
Analysis of Wall Street investments and company research by Bloomberg Intelligence experts.
Sourcery
Interviews with top investors, CEOs, and founders.
Stock Movers
Short conversations analyzing today's biggest gainers and losers in global stock markets across major sectors.
Science Quickly
A bite-sized science podcast exploring discoveries with journalists and experts.
Science Magazine Podcast
Weekly episodes covering original scientific research, global science news, and expert commentary.
Pocket Science
Explores surprising and innovative research happening in Seattle through conversations with local scientists.
The AI XR Podcast.
Insightful interviews with tech founders and executives on AI, virtual reality, augmented reality, and the future of spatial computing.
The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch
Interviews with top venture capitalists and successful founders about startup funding and building tech companies.
Everybody's Business
A weekly look at business news from Wall Street to unusual ventures, with insights from Bloomberg Businessweek journalists.
Moonshots with Peter Diamandis
Exploring breakthrough technologies and their impact on humanity's future.
About BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from BioSpace in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's BioSpace daily summary?
It's a free AI-powered email that summarizes new episodes of BioSpace as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the BioSpace podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official BioSpace product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by BioSpace.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does BioSpace release new episodes?
BioSpace publishes daily. Our AI generates a summary within hours of each new episode.
What topics does BioSpace cover?
BioSpace covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting BioSpace summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.